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A B S T R A C T 
Introduction: Stereotactic brain radiosurgery 
provides good local control in patients with limited 
brain metastases. A newly developed frameless 
system allows pain-free treatment. We reviewed 
the effectiveness of this frameless stereotactic brain 
radiosurgery and identified prognostic factors that 
may aid better patient selection.
Methods: Medical records of patients with brain 
metastases treated with linear accelerator–based 
frameless stereotactic brain radiosurgery between 
January 2010 and July 2015 in a university affiliated 
hospital in Hong Kong were reviewed. Outcomes 
including local and distant brain control rate, 
progression-free survival, and overall survival were 
analysed. Prognostic factors were identified by 
univariable and multivariable analyses. Association 
of outcomes with four common prognostic scores 
was performed.
Results: In this study, 64 patients with 94 lesions were 
treated with a median dose of 18 Gy (range, 12-22 
Gy) in a single fraction. The median follow-up was 
11.5 months. One-year actuarial local and distant 
brain control rates were 72% and 71%, respectively. 
The median overall survival was 13.0 months. On 
multivariable analysis, Karnofsky performance 
status score (>50 vs ≤50) and number of lesions (1-2 
vs ≥3) were found to associate significantly with 
distinct brain progression-free survival (P=0.022, 
hazard ratio=0.20, 95% confidence interval 0.05-
0.80 and P=0.003, hazard ratio=0.31, 95% confidence 
interval 0.14-0.68, respectively). Overall survival was 
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Introduction
Patients with brain metastases have previously 
had poor survival of only 3 to 4 months with non-
surgical treatment.1,2 Substantial improvement has 
been achieved in recent years with the advance 
of systemic treatment and radiation techniques. 
New knowledge added by this study
• Survival of patients with brain metastases has significantly improved over the past decade.
• Frameless stereotactic brain radiosurgery is effective and has acceptable toxicities.
Implications for clinical practice or policy
• Calculation of a prognostic score can aid clinicians in the identification of patients who will benefit most from 
stereotactic brain radiosurgery.
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Stereotactic radiosurgery (SRS) was first delivered 
with the Cobalt-60 Gamma Knife system by Leksell in 
1951.3 Today, SRS can also be delivered via the linear 
accelerator (LINAC) system and proton beam system. 
It is usually indicated in patients with oligo-brain 
metastases (≤4) with a diameter of less than 4 cm.4 
ORIGINAL ARTICLE
associated significantly with Basic Score for Brain 
Metastases (P=0.031), Score Index for Radiosurgery 
in Brain Metastases (P=0.007), and Graded 
Prognostic Assessment (P=0.003). Improvement 
in overall survival was observed in all groups of 
different prognostic scores.
Conclusion: Frameless stereotactic brain 
radiosurgery is effective in patients with oligo-
metastases of brain and should be increasingly 
considered in patients with favourable prognostic 
scoring.
This article was 
published on 10 Nov 
2017 at www.hkmj.org.
  #  Mok et al #
600 Hong Kong Med J  ⎥  Volume 23 Number 6  ⎥  December 2017  ⎥  www.hkmj.org
用於腦轉移瘤的無框架立體定位放射外科手術：
治療結果和預後評分的評估
莫小婷、甘冠明、曾偉光、潘明駿、龍浩鋒、楊會明、 
楊庭恩、余啟成、黃競浩
引言：立體定位放射外科手術能讓腦轉移瘤患者得到良好的局部控
制。新開發的無框架系統能達致無痛治療。本文回顧此技術的效用，
並找出有助選擇合適患者的預後因素。
方法：回顧香港一所大學教學醫院，在2010年1月至2015年7月期間
腦轉移瘤患者的病歷資料，患者均接受直線加速器結合無框架立體定
向腦放射治療。我們分析腦轉移瘤的局部和遠處控制率，以及無進展
生存期和總生存期的結果。通過單變量和多變量分析確定預後因素，
並找出這些結果與四項常見的預後評分是否相關。
結果：本研究中，64名（94個病變）腦轉移瘤患者每次接受劑量的中
位數為18 Gy（介乎12-22 Gy）。隨訪期中位數11.5個月。一年統計
局部和遠處腦部控制率分別為72%和71%。生存期中位數13.0個月。
多變量分析中，發現Karnofsky行為狀態評分表（>50比≤50）和病
變數目（1-2比≥3）與腦部無進展生存顯著相關（P=0.022，風險比
=0.20，95%置信區間0.05-0.80；P=0.003，風險比=0.31，95%置信
區間0.14-0.68）。總體生存率與腦轉移基本評分（P=0.031）、放射
治療分級指數（P=0.007）和等級預後評估標準（P=0.003）顯著相
關。所有預後評分的不同組別的生存期均有整體改善。
結論：無框架立體定向腦放射外科手術對腦轉移瘤患者具成效，應使
用在有良好預後評分的患者中。
It is particularly advantageous for lesions in the deep 
brain parenchyma that are not easily accessible by 
surgery. A frame-based system was initially used 
to immobilise the patient. A frameless system was 
later developed to minimise patient suffering and 
was reported to have comparable outcomes to 
the framed-based system.5 Since the introduction 
of a frameless system, SRS or even fractionated 
stereotactic radiotherapy has been increasingly 
used to treat patients with oligo-brain metastases. 
Patients do not have to undergo painful frame 
placement. Rather, they undergo simple planning 
procedures over 2 consecutive days. The patient 
is required to return only for mould fitting and 
planning of computed tomography. Together with 
diagnostic fine-cut magnetic resonance imaging co-
registration, oncologists can easily contour the target 
on the radiotherapy planning system. With the use 
of the ExacTrac system (Brainlab AG, Germany) to 
verify treatment position, the magnitude of error is 
reported to be only 0.7 mm, and the mean deviation 
between frame-based and image-guided initial 
positioning is just 1.0 mm (standard deviation, 0.5 
mm).6 A frameless system became one of the choices 
of treatment in SRS and was included in the ASTRO 
policy.7 The recommended dosages according to the 
RTOG 9005 trial are 24 Gy, 18 Gy, and 15 Gy for 
tumours of ≤20 mm, 21-30 mm, and 31-40 mm in 
maximum diameter, respectively.8 For framed SRS, 
1-year local progression-free survival (PFS) was 
reported to be up to 70% to 90%, and median overall 
survival (OS) of 6 to 12 months.9-15 The outcomes of 
frameless SRS have been reported only in limited 
series, with 1-year local control of 79% to 95%.5,16-18
 Patient selection and tailor-made management 
are indeed challenging. Several scoring systems have 
been modelled to predict survival of patients with 
brain metastases, including the Radiation Therapy 
Oncology Group Recursive Partitioning Analysis 
(RTOG RPA),19 Basic Score for Brain Metastases 
(BSBM),20 the Score Index for Radiosurgery in Brain 
Metastases (SIR),21 Graded Prognostic Assessment 
(GPA),22 and Disease-Specific Graded Prognostic 
Assessment (DS-GPA).23 These scoring systems were 
developed at a time when treatment strategies were 
also rapidly evolving with the availability of more 
accurate diagnostic imaging, better radiotherapy 
techniques, and more effective systemic and 
targeted agents. A paradigm shift to more aggressive 
treatment of oligo-metastasis as a result of longer 
cancer survivorship now requires further validation 
of these scoring systems. 
 In this study, we reviewed the outcomes of 
patients who underwent LINAC-based frameless 
SRS and identified prognostic factors that affect 
survival. By doing so, we hope to gain a better 
understanding of which patients will benefit from 
SRS without jeopardising their quality of life.
Methods
Records of patients who underwent frameless SRS 
for limited brain metastases in a university-affiliated 
hospital between January 2010 and July 2015 were 
retrospectively reviewed. Patient data were extracted 
from paper records and the Clinical Management 
System of the Hospital Authority, Hong Kong by 
investigators in charge of the study. Data extracted 
included gender, age, type of primary malignancy, 
date of diagnosis of malignancy and brain metastases, 
extracranial disease status and control at treatment 
time, diagnostic and monitoring modalities, presence 
of convulsions, and steroid and anticonvulsant 
use before and after treatment period. Treatment 
details including immobilisation technique, number 
of lesions, dose and fractionation, and volume of 
lesions were reviewed from department records and 
the Brainlab iplan system (Brainlab AG, Germany). 
Prognostic scoring including RTOG RPA, BSBM, 
SIR, and GPA were calculated (Appendix 119-23). 
 Outcome parameters including local and 
distant brain control, PFS, and OS were generated 
using SPSS (Windows version 22.0; IBM Corp, 
Armonk [NY], US). Univariable analysis with Cox 
proportional hazards model was performed to 
generate prognostic factors for local and distinct 
brain PFS (defined as the time from treatment 
to documented local progression/distinct brain 
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progression or death) and OS. For each outcome, 
statistically significant non-modifiable patient and 
disease factors in univariable analysis together 
with important treatment factors were included 
in respective multivariable analysis using Cox 
proportional hazards model. The enter method was 
used for variable selection process. Kaplan-Meier 
survival curve for OS was generated for different 
prognostic scoring groups and log rank significance 
was calculated. The study was approved by clinical 
research ethics committee of the NTEC-CUHK 
Cluster, Hospital Authority, Hong Kong, with patient 
informed consent waived. 
Results
Demographics 
A total of 68 patients were screened during the 
study period. Four patients who were treated with 
fractionated stereotactic radiotherapy and single-
fraction SRS in the same treatment were excluded, 
and thus 64 patients were included. All patients 
were treated with frameless LINAC-based SRS with 
ExacTrac system verification, while contouring and 
dosimetry with the Brainlab iplan system. Dose 
administered was based on tumour diameter: 22 Gy 
to lesions of ≤2 cm, 18 Gy to lesions of 2.1-3.0 cm, 
and 15 Gy to lesions of 3.1-4.0 cm. A 1.5-mm margin 
was allowed from gross tumour volume to planning 
target volume. Deviation of dose prescription 
from departmental protocol was permitted at the 
individual physician’s discretion. 
 Among the 64 patients, there were 40 men and 
24 women. The median age at the time of treatment 
was 58 years (range, 22-95 years). The median 
Eastern Cooperative Oncology Group performance 
status was 1 (range, 0-3), and Karnofsky Performance 
Status (KPS) score was 80 (range, 40-100). Primary 
disease included carcinoma of breast (n=7), lung 
(n=45), gastrointestinal (n=2), renal cell (n=6), 
thyroid (n=1), osteosarcoma (n=1), germ cell (n=1), 
and epithelioid haemangioendothelioma (n=1). 
Further details of demographics are summarised in 
Table 1.
Treatment 
A total of 94 lesions were treated with a dose of 12 
Gy to 22 Gy according to size (12 Gy, n=6; 15 Gy, 
n=12; 16 Gy, n=2; 18 Gy, n=48; 20 Gy, n=14; 22 Gy, 
n=12). The median dose was 18 Gy. The median size 
of lesion treated was 19 mm (range, 3-43 mm).
Outcomes
The median follow-up time was 11.5 (range, 0.4-
56.4) months. One-year actuarial local control rate 
was 72% (95% confidence interval [CI], 57%-83%) 
and distant control rate was 71% (95% CI, 56%-82%). 
The median local PFS was 11.2 (95% CI, 8.4-11.2) 
months. The median distinct brain PFS was 10.8 
(95% CI, 8.4-13.1) months. The median OS was 13.0 
(95% CI, 10.6-11.3) months.
Toxicities
Four (6.3%) patients had acute toxicities, mainly 
brain oedema, and one patient had a seizure for 
3 days after treatment. Eight (12.5%) patients 
had delayed seizure after a median time of 10.5 
months. One patient had radionecrosis confirmed 
pathologically after surgical resection. There were 43 
(67.2%) patients who were prescribed steroid before 
treatment, and eight (12.5%) patients became steroid 
dependent until their demise. Steroid prescription 
was not found to affect OS significantly. Nonetheless 
among the steroid group, becoming steroid 
dependent was associated with poorer prognosis, 
with a median OS in the steroid-dependent group of 
0.92 months versus 13.6 months in the non–steroid-
dependent group (P<0.005, log rank; Appendix 2, Fig 
a). The worse survival of steroid-dependent patients 
was independent of volume of brain metastases.
Prognostic patient and disease factors
Potential prognostic factors of survival including 
patient factors such as gender, age, and performance 
status; and disease factors such as primary cancer, 
presence of extracranial disease, pre-existing 
convulsion, number of brain lesions, and size and 
volume of the largest lesion were examined with 
reference to decision for SRS treatment by univariable 
analysis using Cox proportional hazards model. 
It was found that OS was associated significantly 
with age (≤70 vs >70 years; P=0.011) and KPS score 
(>50 vs ≤50; P=0.008). Local PFS was associated 
significantly with age (≤70 vs >70 years; P=0.043) 
and KPS score (>50 vs ≤50; P=0.021). Distinct brain 
PFS was associated significantly with age (≤70 vs 
>70 years; P=0.02), presence of extracranial disease 
(presence vs absence; P=0.038), KPS score (>50 vs 
≤50; P=0.009), and number of brain lesions (<1-2 
vs ≥3; P=0.016). Results of univariable analysis are 
summarised in Table 2.
Treatment factors
Dose relationship
Dose relationship for each lesion was analysed 
separately. Lesions prescribed >18 Gy had 
statistically significant superior time to progression 
(radiologically documented local progression) than 
those given ≤18 Gy, with a 1-year local control rate 
of 88% vs 60% (Appendix 2, Fig b). Some patients had 
more than one lesion treated with different doses. 
Nonetheless after taking into account the highest 
dose given in the same patient, dose did not affect 
local PFS or OS significantly (Table 2); dose was not 
analysed in distinct brain PFS as it should not affect 
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TABLE 1.  (cont'd)
No. (%) of 
patients
Presence of extracranial metastases
Yes 42 (65.6)
No 22 (34.4)
No. of brain lesions
1 37 (57.8)
2 16 (25.0)
3 8 (12.5)
4 1 (1.6)
≥5 2 (3.1)
Imaging modality
At treatment
CT only 5 (7.8)
CT and MRI 59 (92.2)
Monitoring
CT 35 (54.7)
PET-CT 3 (4.7)
MRI 16 (25.0)
WBS I131 1 (1.6)
Nil 9 (14.1)
Pre-existing convulsion
Yes 11 (17.2)
No 53 (82.8)
Breakthrough convulsion
Yes 8 (12.5)
No 56 (87.5)
Steroid use during SRS
Yes 43 (67.2)
No 19 (29.7)
Unknown 2 (3.1)
Steroid dependent afterwards
Yes 8 (12.5)
No 54 (84.4)
Unknown 2 (3.1)
WBRT
WBRT >3 months before 10 (15.6)
Concomitant WBRT 25 (39.1)
Salvage WBRT 9 (14.1)
Lifelong WBRT 43 (67.2)
Progressive disease after SRS
Local 10 (15.6)
Distinct 23 (35.9)
Salvage treatment on disease progression
WBRT 9 (14.1)
SRS 1 (1.6)
Surgery 1 (1.6)
TABLE 1.  Demographics and treatment details
No. (%) of 
patients
Gender
Male 40 (62.5)
Female 24 (37.5)
Age-group (years)
18-30 2 (3.1)
31-40 6 (9.4)
41-50 11 (17.2)
51-60 18 (28.1)
61-70 18 (28.1)
71-80 8 (12.5)
>80 1 (1.6)
Primary malignancy (subtype)
Breast 7 (10.9)
Luminal A 1
Luminal B 4
Her2 2
Basal-like 0
Lung 45 (70.3)
NSCLC/adenoCa NOS 16
NSCLC/adenoCa unknown mutation 1
NSCLC/adenoCa EGFR mutant* 17
ALK+ 3
SqCC 5
SCLC 2
Unknown 1
Gastrointestinal 2 (3.1)
Renal cell carcinoma 6 (9.4)
Thyroid (papillary) 1 (1.6)
Osteosarcoma 1 (1.6)
Germ cell 1 (1.6)
Epithelioid haemangioendothelioma 1 (1.6)
ECOG performance status
0 5 (7.8)
1 41 (64.1)
2 15 (23.4)
3 3 (4.7)
Extracranial disease control
Uncontrolled 27 (42.2)
Controlled 22 (34.4)
Complete remission 15 (23.4)
Abbreviations: adenoCa = adenocarcinoma; ALK+ = anaplastic 
lymphoma kinase positive; CT = computed tomography; ECOG 
= Eastern Cooperative Oncology Group; EGFR = epidermal 
growth factor receptor; Her2 = human epidermal growth factor 
receptor 2; MRI = magnetic resonance imaging; NOS = not 
otherwise specified; NSCLC = non–small-cell lung carcinoma; 
PET-CT = positron emission tomography–computed tomography; 
SCLC = small-cell lung cancer; SqCC = squamous cell carcinoma; 
SRS = stereotactic radiosurgery; WBRT = whole-brain 
radiotherapy; WBS I131 = whole-body scan iodine 131
* adenoCa EGFR mutant (exon 19 deletion: n=8; exon L858R 
mutant: n=6; exon 18 missense mutant: n=1; exon 19 179S 
mutant: n=1; exon 21 L861Q mutant: n=1)
#  Frameless stereotactic radiosurgery  # 
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distant brain progression.
Effect of whole-brain radiotherapy 
With particular reference to the effect of whole-brain 
radiotherapy (WBRT), it was found that concomitant 
WBRT (within 3 months of treatment with SRS) did 
not have a statistically significant impact on OS, 
local PFS, or distant brain PFS (Table 2). 
Multivariable analysis
Multivariable analysis using Cox proportional 
hazards model and taking patient, disease, and 
treatment factors into account identified that 
statistically significant factors associated with 
distinct brain PFS were KPS score (>50 vs ≤50; 
P=0.022, hazard ratio [HR]=0.20, 95% CI=0.05-0.80) 
and number of brain lesions (1-2 vs ≥3; P=0.003, 
HR=0.31, 95% CI=0.14-0.68) [Table 3].
Primary lung cancer
Of note, a large number of patients in the group 
had primary lung cancer (n=45), most of which 
were non–small-cell lung cancer (NSCLC) [n=42]. 
Among NSCLC patients, a sensitive activating 
EGFR mutation (exon 19 deletion or exon 21 L858R 
mutation) was present in 14. Three other patients 
FIG.  Overall survival (OS) according to prognostic score grouping: (a) RTOG RPA, (b) BSBM, (c) SIR, and (d) GPA 
Abbreviations: BSBM = Basic Score for Brain Metastases; GPA = Graded Prognostic Assessment ; RTOG RPA = Radiation Therapy Oncology Group 
Recursive Partitioning Analysis; SIR = Score Index for Radiosurgery in Brain Metastases
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Abbreviations: CI = confidence interval; HR = hazard ratio; KPS = Karnofsky performance status; N/A = not applicable; PFS = progression-free survival; 
WBRT = whole-brain radiotherapy
* Data were missing for two cases
TABLE 2.  Univariable analysis by categorical variables
Variable No. (%) of 
patients
Local PFS Overall survival Distinct brain PFS
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Patient factors
Gender
Male 40 (62.5) 1.21 (0.69-2.14) 0.502 1.249 (0.69-2.27) 0.47 1.02 (0.58-1.77) 0.95
Female 24 (37.5)
Age (years)
≤70 56 (87.5) 0.45 (0.21-0.97) 0.043 0.61 (0.40-0.89) 0.011 0.40 (0.19-0.86) 0.02
>70 8 (12.5)
KPS score
>50 61  (95.3) 0.49 (0.27-0.90) 0.021 0.43 (0.23-0.80) 0.008 0.44 (0.24-0.81) 0.009
≤50 3  (4.7)
KPS score
≥80 46 (71.9) 0.74 (0.41-1.34) 0.32 0.63 (0.34-1.17) 0.149 0.78 (0.43-1.44) 0.43
<80 18 (28.1)
Disease factors
Primary cancer
Lung 45 (70.3) 1.12 (0.62-2.02) 0.71 1.01 (0.74-1.38) 0.95 1.18 (0.65-2.12) 0.59
Non-lung 19 (29.7)
Presence of extracranial disease
Presence (disease under control/
not under control)
49 (76.6) 1.25 (0.90-1.73) 0.19 1.41 (2.98-2.01) 0.06 2.06 (1.04-4.08) 0.038
Complete remission (no disease 
except brain)
15 (23.4)
No. of brain lesions
1-2 53 (82.8) 0.76 (0.54-1.08) 0.127 0.73 (0.51-1.04) 0.08 0.66 (0.46-0.93) 0.016
≥3 11 (17.2)
Pre-existing convolution
Presence 11 (17.2) 1.12 (0.79-1.59) 0.52 1.06 (0.73-1.52) 0.78 1.04 (0.73-1.49) 0.83
Absence 53 (82.8)
Size of the largest lesion (mm)
<20 35 (54.7) 0.83 (0.63-1.09) 0.18 0.65 (0.36-1.16) 0.15 0.86 (0.65-1.13) 0.29
≥20 29 (45.3)
Volume of the largest lesion (mL)
<10 33 (51.6) 1.28 (0.71-2.12) 0.46 1.38 (0.77-2.46) 0.27 1.26 (0.72-2.18) 0.42
≥10 31 (48.4)
Treatment factors
Dose (Gy)
>18 (any lesion in the same patient) 20 (31.3) 0.78 (0.57-1.07) 0.12 0.84 (0.61-1.15) 0.15 N/A N/A
≤18 44 (68.8)
Concomitant WBRT 
Yes 25 (39.1) 0.85 (0.64-1.13) 0.27 0.90 (0.67-1.22) 0.51 0.89 (0.67-1.18) 0.43
No 39 (60.9)
Steroid use*
Yes 43 (67.2) 1.24 (0.91-1.70) 0.17 1.36 (0.96-1.91) 0.081 1.16 (0.85-1.58) 0.36
No 19 (29.7)
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carried a less common mutation: exon 21 861Q 
(n=1), exon 18 missense (n=1), and exon 18 179S 
(n=1). Patients with an exon 19 deletion or exon 21 
L858R mutation had superior OS compared with 
the non-mutational group (P=0.019, HR=0.281, 
95% CI=0.097-0.814) but there was no statistically 
significant difference in local or distant brain control. 
Among the 14 patients with sensitive activating 
EGFR mutation, three patients who were diagnosed 
with brain metastases received WBRT before SRS 
treatment, and six patients were given SRS together 
with WBRT. Again, concomitant WBRT was not 
shown to affect local/distinct brain PFS or OS. For 
epidermal growth factor receptor (EGFR)–tyrosine 
kinase inhibitor (TKI) treatment, 12 of 14 patients 
had lifelong EGFR-TKI treatment, with a median 
survival of 19.5 months; one with exon 19 deletion 
and one with exon 18 missense deletion did not have 
EGFR-TKI treatment. There were seven patients who 
were prescribed EGFR-TKI before SRS treatment 
(range of duration, 5.7-21.4 months), and eight 
patients who were started on or continued on more 
TABLE 3.  Multivariable analysis by categorical variables with Cox regression model
Abbreviations: CI = confidence interval; HR = hazard ratio; KPS = Karnofsky performance status; N/A = not applicable; PFS = progression-free survival; 
WBRT = whole-brain radiotherapy
lines of EGFR-TKI after SRS treatment. 
Association with available prognostic scoring
Overall survival was significantly associated with 
BSBM (P=0.031, log-rank), SIR (P=0.007, log-rank), 
and GPA (P=0.003, log-rank) [Fig]. A comparison of 
median survival of the current study with the other 
original studies is shown in Table 4.19-22 Of note, 
DS-GPA was not analysed due to the small number 
of patients with breast, gastrointestinal, and renal 
cell primaries. The calculation of GPA and DS-GPA 
of lung primary was the same. 
Discussion
Brain metastasis has previously been considered 
an end-of-life event. With the development of 
new systemic therapies that are effective in both 
extracranial and intracranial diseases, together with 
a better understanding from clinical trials of the 
advantages of SRS, oncologists are more willing to 
offer SRS to patients with limited brain metastases.
Variable Local PFS Overall survival Distinct brain PFS
Median 
survival 
(months)
HR (95% CI) P value Median 
survival 
(months)
HR (95% CI) P value Median 
survival 
(months)
HR (95% CI) P value
Age (years)
≤70 11.3 0.84 (0.54-1.32) 0.45 13.4 0.76 (0.48-1.21) 0.25 11.3 0.42 (0.16-1.06) 0.067
>70 3.3 3.4 2.5
KPS score
>50 11.3 0.61 (0.31-1.18) 0.14 13.4 0.27 (0.07-1.00) 0.068 11.3 0.20 (0.05-0.80) 0.022
≤50 4.7 4.7 2.4
Presence of extracranial 
disease
N/A N/A 
Presence (uncontrolled/
controlled) 
9.0 1.10 (0.55-2.22) 0.78
Absence 17.0
No. of brain lesions N/A N/A
1-2 11.3 0.31 (0.14-0.68) 0.003
≥3 5.8
Dose (Gy) N/A 
>18 11.4 0.77 (0.55-1.06) 0.11 19.1 0.87 (0.62-1.21) 0.40
≤18 9.8 13.0
Concomitant WBRT
Yes 12.9 0.81 (0.58-1.12) 0.20 13.6 0.90 (0.64-1.26) 0.53 12.9 0.56 (0.45-1.66) 0.66
No 7.4 10.7 7.4
Steroid use
Yes 9.0 1.25 (0.89-1.76) 0.19 11.4 1.32 (0.91-1.91) 0.15 10.4 1.29 (0.63-2.66) 0.48
No 14.0 21.5 11.3
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Abbreviations: BSBM = Basic Score for Brain Metastases; GPA = 
Graded Prognostic Assessment; RTOG RPA = Radiation Therapy 
Oncology Group Recursive Partitioning Analysis; SIR = Score 
Index for Radiosurgery in Brain Metastases
TABLE 4.  Comparison of median overall survival in the present 
study according to prognostic scoring group with that of 
original studies19-22
Median overall survival time (months)
Original study Present study
RTOG GPA,19 1997
I 7.7 35.5
II 4.5 13.0
III 2.3 6.7
BSBM,20 2004
3 7.0 35.5
2 5.1 13.7
1 3.4 11.4
0 2.2 6.7
SIR,21 2000
8-10 8.8 35.5
4-7 6.0 13.0
1-3 2.1 4.7
GPA,22 2008
3.5-4.0 11.0 35.5
3 6.9 13.7
1.5-2.5 3.8 13.4
0-1.0 2.6 4.1
 At the other extreme, studies have compared 
the efficacy of WBRT with supportive care in patients 
with advanced brain metastases. The latest news from 
the QUARTZ trial, conducted by the UK Medical 
Research Council Group, presented at the American 
Society of Clinical Oncology Meeting in 201524 (full 
paper awaited) was striking for oncologists. They 
randomly allocated 538 NSCLC patients with brain 
metastases that were not amenable to surgery or 
SRS to either optimal supportive care (OSC) plus 
WBRT (20 Gy/5 fractions) or OSC alone. There was 
no significant difference in survival between the 
OSC+WBRT group and OSC-alone group, with the 
median survival being 65 and 57 days, respectively. 
Quality of life was also assessed in this study. The 
difference between the mean quality-adjusted 
life-years was -1.9 days only (OSC+WBRT 43.3 vs 
OSC-alone 41.4 days) and did not meet the initial 
defined criteria of significance. These data revealed 
that we are encountering a group of patients with 
very heterogeneous tumour behaviour and thus 
personalised treatment is required.
 This retrospective study included patients who 
underwent frameless SRS during January 2010 to 
July 2015, after commencement of frameless SRS 
treatment in our centre. Limitations of this study 
including small number of patients and information 
bias are inevitable. Nonetheless, the outcomes of 
patients with brain metastases who underwent 
frameless SRS in our centre are compatible with 
those from other large clinical trials that used 
frame-based systems in terms of control rate, 
median OS and PFS, and toxicities. Approximately 
13% of patients had a complication of steroid 
dependence that may have been due to treatment 
or natural disease progression. Steroid dependence 
was associated with poor survival, independent 
of volume of tumour. Prolonged use of steroid has 
been associated with decreased immunity that 
may underlie superimposed infection. Therefore, 
tailing down of steroid dose as early as possible 
in accordance with patient symptoms is strongly 
recommended.
 This study revealed that OS was significantly 
associated with previously identified prognostic 
scoring group such as BSBM, SIR, and GPA. Among 
the three, BSBM and GPA are more convenient 
to use as only three or four factors are considered 
respectively, and the information should be easily 
available in a clinic (including age, KPS, control of 
primary cancer, presence of extracranial metastases, 
and number of brain metastases). Data relating 
to volume of the largest brain lesion included in 
SIR may not always be available as the reporting 
radiologist may only report lesion diameter. In 
terms of patient selection, for patients with GPA of 
0-1.0, the median OS was 4.1 months in our study 
compared with 2.6 months in the original study, and 
similar to that of patients given WBRT alone. It may 
be more appropriate to prescribe WBRT alone or 
best supportive care for this group of patients in lieu 
of SRS. An important observation from the result of 
our study is that survival of patients was significantly 
improved compared with a previous cohort (Table 4). 
This reflects a significant improvement in systemic 
treatment over the last decade. Thus, the use of 
high technology radiation techniques such as SRS is 
increasingly considered by radiation oncologists to 
achieve the best outcomes.
 Another important aim of this study was to 
identify prognostic factors of survival in order to 
avoid futile treatment in those patients who will 
have a poor outcome despite SRS. Due to the small 
number of patients in this study, we were not able 
to identify patients with superior survival among 
different primaries, similar to DS-GPA. It is of 
note that a large number of patients in our study 
had primary lung cancer. In the NSCLC subgroup, 
patients with an activating EGFR mutation had 
significantly better survival than those without 
mutation, and the majority of this group had EGFR-
TKI lifelong. Of note, EGFR-TKI has been shown 
in various studies to have PFS and survival benefit 
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in patients with EGFR-activating mutation.25-32 In a 
recent retrospective multi-institutional study with 
more than 300 patients, outcomes of patients with 
EGFR-activating mutation were analysed following 
treatment with upfront SRS followed by EGFR-TKI, 
upfront WBRT followed by EGFR-TKI, and upfront 
EGFR-TKI.33 Patients in the upfront SRS and upfront 
WBRT group had significantly superior OS and 
intracranial PFS compared with those with upfront 
EGFR-TKI.33 Therefore, in patients with oligo-brain 
metastases harbouring an EGFR-activating mutation, 
SRS followed by EGFR-TKI should be considered 
a standard treatment, and WBRT reserved until 
there is frank brain disease progression to conserve 
cognitive function. In addition, SRS combined with 
efficacious systemic treatment with good brain 
penetration while omitting WBRT should also be 
considered in other primaries, although further 
studies are awaited to validate the benefit.
 The beneficial effect of WBRT in addition to SRS 
is controversial. Recent evidence shows it improves 
local control but not survival.34,35 Nonetheless, in 
view of toxicity of somnolence, malaise and cognitive 
impairment with WBRT, many clinicians may 
prefer delaying WBRT until there is frank disease 
progression after SRS. In a recent meta-analysis, 
the benefit of additional WBRT was not observed in 
patients who were 50 years old or younger in terms 
of survival or distant brain control.36 Initial omission 
of WBRT in this young age-group had no adverse 
effect on distant brain relapse rate. We were unable 
to replicate improvement in brain control with 
WBRT or demonstrate an interaction of age with 
benefit of concomitant WBRT, possibly due to the 
small size and retrospective nature of our current 
study. Number of brain metastases was identified as 
a significant prognostic factor of brain PFS. Patients 
with three or more brain metastases had worse PFS 
than those with one or two brain metastases (5.8 
months vs 11.3 months). Again due to the small 
number of patients, we were unable to demonstrate 
whether concomitant WBRT could improve brain 
PFS in patients with three or more brain metastases. 
Further prospective studies are warranted to verify 
whether concomitant WBRT should be considered 
in patients with a higher disease load or age over 50 
years.
 Frameless SRS for oligo-brain metastases is 
painless and well tolerated, and should be increasingly 
considered in patients with good prognostic scores. 
Its combination with effective systemic treatment 
has significantly improved survival over the past 
decade. Nonetheless it is important to individualise 
treatment for patients with brain metastases 
according to their inherited prognostic risk factors. 
High precision treatment with SRS with or without 
WBRT should be offered to patients with oligo-
brain metastases with good prognostic scores and 
favourable primary histology. For patients with 
EGFR-activating mutation, SRS followed by EGFR-
TKI is a superior choice of treatment. Based on 
the latest evidence, it may be advisable to give SRS 
alone and reserve WBRT as salvage for patients 
with limited brain metastases who are 50 years or 
younger. Further, WBRT alone can be offered to 
patients with multiple symptomatic brain metastases 
and unfavourable prognostic scores. Best supportive 
care with dexamethasone alone may be considered 
for patients with very poor performance status. 
Conclusion
Frameless SRS is effective and safe for patients with 
oligo-metastases of brain. Identification of patients 
with brain metastases who would benefit from SRS 
is important. Current available prognostic scoring 
systems provide a good estimation of survival. 
Frameless SRS should be increasingly considered in 
patients with favourable prognostic scores.
Appendices
Additional material related to this article can be 
found on the HKMJ website. Please go to <http://
www.hkmj.org>, and search for the article.
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